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a b s t r a c t
The long bones of the vertebrate body are built by the initial formation of a cartilage template that is later
replaced by mineralized bone. The proliferation and maturation of the skeletal precursor cells
(chondrocytes) within the cartilage template and their replacement by bone is a highly coordinated
process which, if misregulated, can lead to a number of defects including dwarﬁsm and other skeletal
deformities. This is exempliﬁed by the fact that abnormal bone development is one of the most common
types of human birth defects. Yet, many of the factors that initiate and regulate chondrocyte maturation
are not known. We identiﬁed a recessive dwarf mouse mutant (pug) from an N-ethyl-N-nitrosourea
(ENU) mutagenesis screen. pug mutant skeletal elements are patterned normally during development,
but display a 20% length reduction compared to wild-type embryos. We show that the pug mutation
does not lead to changes in chondrocyte proliferation but instead promotes premature maturation and
early ossiﬁcation, which ultimately leads to disproportionate dwarﬁsm. Using sequence capture and
high-throughput sequencing, we identiﬁed a missense mutation in the Xylosyltransferase 1 (Xylt1) gene in
pug mutants. Xylosyltransferases catalyze the initial step in glycosaminoglycan (GAG) chain addition to
proteoglycan core proteins, and these modiﬁcations are essential for normal proteoglycan function.
We show that the pugmutation disrupts Xylt1 activity and subcellular localization, leading to a reduction
in GAG chains in pug mutants. The pug mutant serves as a novel model for mammalian dwarﬁsm and
identiﬁes a key role for proteoglycan modiﬁcation in the initiation of chondrocyte maturation.
& 2013 Elsevier Inc. All rights reserved.
Introduction
One of the deﬁning features of vertebrates is their internal
skeleton. While the global organization of the skeleton is con-
served across vertebrates, changes in the number, size, or shape of
speciﬁc skeletal elements correspond to newly acquired or mod-
iﬁed structures induced through evolutionary pressure. Within a
species, however, the organization and morphology of skeletal
elements are much more constrained; suggesting that tight
regulation of skeletal development is essential for an animal's
reproductive ﬁtness. Most skeletal elements in the appendicular
and axial skeleton of the vertebrate body are formed through
the process of endochondral ossiﬁcation that involves the
formation of a cartilage anlage, within which chondrocytes undergo
a maturation process before being replaced by mature bone. This
process begins with the condensation and aggregation of
mesenchymal cells, which then differentiate into chondrocytes
(Shimizu et al., 2007). As the cartilage anlage grows, the chon-
drocytes become arranged into morphologically distinct zones of
resting, proliferative, prehypertrophic, and hypertrophic chondro-
cytes, called growth plates (Goldring et al., 2006). Progression
through the growth plates occurs as chondrocytes mature, result-
ing in the most mature cells located near the center of the skeletal
element. While bone is laid down in the center of the anlage by
invading osteoblasts, the element continues to grow on either end
within the growth plates via highly regulated proliferation of a
subset of the chondrocyte pool. This process, if misregulated, leads
to skeletal abnormalities that can affect the size, shape and
strength of skeletal elements (Baldridge et al., 2010).
Multiple signaling pathways regulate chondrogenesis, and tight
regulation of their signaling output is critical for normal skeletal
development. For example, achondroplasia, the most common
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form of human dwarﬁsm, is associated with excess Fibroblast
growth factor (Fgf) signaling due to activating mutations in Fgfr3.
This results in the rhizomelic shortening of limb bones, or a more
severe shortening of proximal limb elements compared to distal
elements (Deng et al., 1996; Ornitz, 2005; Rousseau et al., 1994;
Segev et al., 2000). Signaling molecules such as Indian Hedgehog
(Ihh) and Parathyroid hormone related protein (PTHrP) (Retting
et al., 2009; Shimizu et al., 2007) also regulate chondrogenesis and
maturation. A loss of either PTHrP or its receptor, PTH1R, results in
reduced skeletal element size and premature maturation, while a
loss of Ihh results in reduced skeletal elements size due to delayed
maturation and a disorganization of the growth plate (Karaplis
et al., 1994; Lanske et al., 1996; Vortkamp et al., 1996). Though
these signaling pathways each have speciﬁc roles, they do not act
in isolation; crosstalk between the major pathways helps to
maintain the proper rate and coordination of chondrocyte matura-
tion to create an appropriately sized and patterned skeleton
(Amizuka et al., 2004; Kronenberg, 2003; Minina et al., 2002).
Normal endochondral ossiﬁcation also depends upon a distinct
and complex extracellular matrix (ECM) comprising cartilage-
speciﬁc collagens, elastin, and proteoglycans. The ECM functions
both as a structural component for the skeleton, especially at the
joints, but also as a regulator of signaling molecule diffusion and
function within the growth plate. Signaling factors must traverse
and interact with the extracellular matrix in order to induce their
effects. Ihh, expressed in prehypertrophic chondrocytes, signals
both short-range to activate its downstream targets such as
Patched1 (Ptch1) and Gli1, but also long-range to regulate the
expression of PTHrP at the heads of the developing skeletal
elements (Gritli-Linde et al., 2001; Karaplis et al., 1994; Karp
et al., 2000; Kobayashi et al., 2005; Mak et al., 2008; St-Jacques
et al., 1999). This long-range signaling is critical to modulate
maturation of the resting pool of chondrocytes (Kronenberg,
2003; Lanske et al., 1996; Vortkamp et al., 1996). Runx2 also
functions downstream of Ihh in order to regulate maturation from
prehypertrophic to hypertrophic chondrocytes, and is required for
bone formation (Enomoto et al., 2000; Enomoto-Iwamoto et al.,
2001; Takarada et al., 2013; Takeda et al., 2001). Similarly, during
endochondral ossiﬁcation, Fgf7, 8, 9, 17, and 18 are expressed
primarily in the perichondrium, or the ﬁbrous layer of cells
surrounding the condensed chondrocytes, and signal to Fgfr3
expressed on proliferative and resting chondrocytes (Hung et al.,
2007; Liu et al., 2002; Ornitz, 2005). Despite a large body of work
on human bone diseases and animal models, the relationship
between skeletal development and defects in the ECM are
understudied.
To identify factors that regulate skeletal element length, we
took a forward genetics approach and studied a recessive mouse
mutant, pug that was identiﬁed from a N-ethyl-N-nitrosourea
mutagenesis screen. Homozygous pug animals display a dwarﬁsm
phenotype, with shortened long bones compared to their wild
type or heterozygous littermates. However, this is not due to
changes in the proliferation of chondrocytes, but rather to their
early maturation. The premature progression of pug chondrocytes
through the maturation process occurs prior to changes in Ihh and
Fgf signaling, suggesting chondrocyte maturation initiates inde-
pendently of these signaling pathways. We further show that the
underlying genetic defect in pug mutants is a missense mutation
in the Xylosyltransferase 1 (Xylt1) gene. Xylosyltransferases catalyze
a rate-limiting step in the addition of glycosaminoglycan (GAG)
side chains to proteoglycans (Cuellar et al., 2007; Esko et al., 1985;
Kearns et al., 1993; Ponighaus et al., 2007; Prante et al., 2006),
which is critical for proteoglycan function within the extracellular
matrix. We show that Xylt1 is speciﬁcally expressed in chondro-
cytes during embryonic development and, as in other studies,
Xylt1 protein localizes within the cis-Golgi where it functions as a
xylosyltransferase (Nuwayhid et al., 1986; Schön et al., 2006a). We
ﬁnd that pug is a hypomorphic allele of Xylt1 that results both in
reduced Xylt1 activity and altered Xylt1 subcellular localization.
We further show that GAG chain levels are reduced in pugmutants
and these changes likely underlie the dwarﬁsm phenotype. The
defect in proteoglycan processing and subsequent premature
maturation in pug mutants highlights a key role for Xylt1 and
glycosaminoglycans in the regulation of chondrocyte maturation
during skeletal development.
Materials and methods
Mouse strains
The pug mutant was identiﬁed as part of a mutagenesis screen
(described in (Liem et al., 2009)). Brieﬂy, C57BL6/J males were
mutagenized with N-ethyl-N-nitrosourea (ENU) and crossed to
FVB/NJ females. F1 males were further mated to FVB/NJ females to
generate G2 females. Embryos from F1 x G2 crosses were analyzed
for recessive phenotypes. The pug mutant was identiﬁed at
embryonic day (e) 18.5 based on shorter limbs compared to
littermates. PTHrP-LacZ mice were crossed to pug animals and
genotyped as described previously for LacZ (Chen et al., 2006).
Mapping of the pug mutation
Using a whole genome single nucleotide polymorphism (SNP)
panel (Moran et al., 2006), pug was mapped to Chromosome 7 and
the pug interval was subsequently narrowed to between SNP
markers rs31909733 (122.29 Mb) and rs6261444 (130.1 Mb) via
meiotic recombination mapping. The pug mutation has been
crossed 410 generations onto the FVB/NJ background, which
removed more than 99.9% of the original mutagenized C57BL/6J
background, supporting the idea that the pug phenotype is
monogenic. Mutant characterization was carried out at various
stages of crossing into the FVB/NJ background.
Sequence capture
A Nimblegen mouse Sequence Capture 385 K array was
designed to contain oligos complementary to the exons within
the pug genomic locus (NCBI37/mm9 Chr7: 122,297,973–
130,145,967 Mb), minus repetitive sequences. Genomic DNA from
a pug homozygote was isolated and then sheared by sonication,
and adaptors were ligated to the resulting fragments. The adaptor-
ligated templates were fractionated by agarose gel electrophoresis
and fragments of the desired size were excised. Extracted DNAwas
ampliﬁed by ligation-mediated PCR, puriﬁed, and hybridized to
the Sequence Capture array. The array was washed, and bound
DNA was eluted, puriﬁed, and ampliﬁed by ligation-mediated PCR
(similar to methods employed in (Choi et al., 2009)). The capture
and sequencing experiments were performed at the W.M. Keck
Foundation for Biotechnology Resources at Yale. This array also
contained sequences from Chromosomes 4 & 11, unrelated to the
pug locus. For details about these sequences, please contact the
authors.
Sequencing and mutation analysis
Captured libraries were sequenced on an Illumina Genome
Analyzer II as single-end, 75-bp reads using previously described
methods (Choi et al., 2009). Illumina reads were ﬁrst trimmed
based on their quality scores to remove low-quality regions using
the program Btrim (Kong, 2011). A cutoff of 20 for average quality
scores within a moving window of size 5-bp was used. Minimum
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acceptable read length was 25-bp. Other parameters of Btrim were
set to defaults. The pre-processed reads were then aligned to the
mouse genome reference sequence (mm9) using the BWA map-
ping program (Li and Durbin, 2009). The mapping results were
converted into SAMtools pileup format using SAMtools programs
(Li et al., 2009). PCR duplicates were removed using the rmdup
command from SAMtools. Single nucleotide variations (SNVs)
were called using SAMtools' pileup command. Further ﬁltering
was performed using in-house scripts to exclude those SNV calls
that had less than three reads or a SNP score less than 20.
Annotation was added based on the UCSC RefSeq gene model
(http://genome.ucsc.edu/ (Pruitt et al., 2009)).
Stage matching early embryos
To ensure that control and pugmutant embryos from e13 litters
were matched in terms of embryonic development, we paired
embryos based on crown-rump length, measured using an eye-
piece micrometer. Using this comparative method, we observed no
difference in the distribution of crown-rump length between pug
and control embryos, indicating that overall embryo size was
unchanged in the pug mutants at these early stages. We deﬁned
early e13 embryos as having a crown-rump length of 7.9–9.3 mm
while e13.5 embryos were deﬁned as those with a crown-rump
length of 9.35–10.3 mm.
Expression analysis
In situ hybridization and immunoﬂuorescence analysis were
performed using standard methods (Nagy et al., 2002). Antibodies
were obtained from various sources: XYLT1 (1:25–50; Sigma,
Prestige Antibodies, St Louis, MO), GM130 (1:500; BD Biosciences,
Franklin Lakes, NJ), phospho-histone H3 (1:500; Millipore, Teme-
cula, CA) and phospho-44/42 MAPK (i.e. ERK1/2; 1:100; Cell
Signaling, Danvers, MA). OCT and parafﬁn embedded samples
underwent heat-induced epitope retrieval in 10 mM sodium
citrate in the 2100-Retriever (E.M.S., Hatﬁeld, PA) following man-
ufacturer's speciﬁcations. Quantiﬁcations of phospho-44/42 MAPK
and phospho-histone H3 were performed using standard plug-ins
in ImageJ.
Skeletal staining
Embryonic skeletons were prepared and stained with Alcian
Blue and Alizarin Red, then cleared using standard methods (Nagy
et al., 2002). Adult skeletons were processed according to standard
procedures (Selby, 1987). Brieﬂy, animals were skinned, eviscer-
ated and washed in several changes of potassium hydroxide
solution over several days. Following staining with Alizarin Red,
adult tissue was cleared in 2:1:2 mix of glycerin:benzyl alcohol:
70% ethanol.
Histological analysis and staining
Specimens were collected and processed for parafﬁn embed-
ding using standard methods (Nagy et al., 2002). Sections (7 μm)
were cut on a Leitz Leica 1512 microtome and processed with
either Gill's No. 2 hematoxylin followed by 0.5% eosin, or 0.001%
Fast Green (FCF) solution followed by 0.1% Safranin O solution.
Micro computer tomography (μCT)
Micro-CT analyses were performed through the Yale Core
Center for Musculoskeletal Disorders, following standard proce-
dures (Kawano et al., 2013). Brieﬂy, adult animals were euthanized
and the femurs were isolated, stripped of soft tissue and stored in
70% ethanol. The bones were scanned using a Scanco μCT-35
instrument (Scanco, Bruttisellen, Switzerland) as previously
described (Itokowa et al., 2011). Both 2- and 3-D μCT data included
bone volume to total volume fraction (BV/TV), trabecular number
(Tb.N), thickness (Tb.Th), space (Tb.Sp), connectivity density
(Conn.D), structural model index (SMI), and degree of anisotrophy
(DA). Cortical thickness averaged for both cortices (Ct.Th), bone
volume to total volume fraction (Ct.BV/TV), endosteal radius
(endo.radius), periosteal radius (peri.radius), and polar moment
of inertia (pMOI) were also quantiﬁed.
in vivo xylosyltransferase activity assay
Proximal hindlimb cartilage dissected from P0 pug and wild
type limbs was homogenized in 12 mM MgCl2, 4 mM MnCl2
50 mM KCl and 50 mM 4-morpholineethanesulfonic acid (MES)
buffer, pH6.5. Xylosyltransferase activity was determined by the
incorporation of [14C]-D-xylose into either a synthetic bikunin
peptide acceptor or chicken aggrecan as previously described
(Kearns et al., 1991), with minor modiﬁcations. Reaction mixture
contained: 12 mM MgCl2, 4 mM MnCl2, 50 mM KCl, 50 mM MES,
pH 6.5, 7.5 mM KF, 0.2 mg/ml bikunin peptide (QEEEGSGGGQLV)
or 1 mg/ml recombinant aggrecan CS region, 12 mM UDP-xylose
and 0.5 mCi/ml [14C]-UDP-xylose and 60 mg of protein extract per
assay. After incubation at 37 1C for 1 h, for bikunin peptide
reaction products were absorbed onto a AG50W-X2 column,
washed with 0.01 N HCl and eluted with 2 M NH4OH. For aggrecan
protein acceptor, radioactive products were TCA/PTA precipitated.
Incorporated radioactivity was then measure by liquid scintillation
counting.
Cell culture xylosyltransferase assay
Chinese hamster ovary (CHO) and CHO-K1-pgsA-745 (abbre-
viated CHO-745) cell lines were maintained in Ham's F-12 medium
containing 10% FBS, 100 U/ml penicillin G, and 100 μg/ml strepto-
mycin sulfate. CHO-745, deﬁcient in the xylosyltransferase activity
required for the synthesis of both heparan sulfate and chondroitin
sulfate proteoglycans, was kindly provided by J. Esko, University of
California, San Diego (Esko et al., 1985). Triplicate dishes at 70%
conﬂuence were transfected with a construct engineered to
express wild-type Xylt1 or a mutant form of Xylt1 bearing the
pug mutation, using Mirus-LT1 as the transfection reagent and
following the manufacturer's instructions. Forty-eight hours after
transfection cells were collected in 12 mM MgCl2, 4 mM MnCl2,
50 mM KCl and 50 mM 4-morpholineethanesulfonic acid (MES)
buffer, pH6.5 and xylosyltransferase activity determined as
described above using the bikunin peptide as acceptor.
Biosynthetic radiolabeling of proteoglycans with sulfate
Cartilage dissected from P0 wild-type or pug limbs was incu-
bated for 24 h with 200 μCi/ml [35S]H2SO4 in F12 media and then
homogenized in 5 M guanidine, 100 mM E-aminocaprionic acid,
10 mM EDTA, 5 mM benzamidine, 5 mM phenylmethyl-sulfonyl-
ﬂuoride, and 10 mM N-ethylmaleimide. Proteoglycans were pur-
iﬁed by cesium chloride density gradient centrifugation as
described previously (Domowicz et al., 2000), extensively dialyzed
against 100 mM ammonium acetate (pH 7.0) and digested with
chondroitinase ABC (0.5 U/ml) at 37 1C for 4 h in 5 mM EDTA,
100 mM Tris, pH 7.4. Digested and undigested proteoglycan
samples were TCA/PTA precipitated and radioactivity measured
by liquid scintillation counting. Counts were normalized for total
protein in the original homogenate.
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Results
Forward genetics uncovers a chondrodysplastic mouse mutant
Despite recent advances in skeletal biology, the genetic mechan-
isms that balance chondrocyte proliferation and maturation are still
unclear. To uncover new factors that regulate these processes, we took
advantage of an unbiased ENU-induced mutagenesis screen in mice.
We focused on the strictly recessive pugmutant that was ﬁrst detected
due to reduced limb length at embryonic day (e) 18.5. We discovered
that this difference in limb length could be traced back to early stages
suggesting that the pug mutant could provide crucial insight into
skeletal development. At e14.5 we observed an 18% reduction in
stylopod (humerus, femur) element length, and 14% reduction in
zeugopod (radius/ulna, tibia/ﬁbula) length in pugmutants (Fig. 1A). By
e16.5, both the pug stylopod and zeugopod are 18% shorter than
controls and this disparity remains until late embryonic stages (Fig. 1A,
D and E). While the crown-rump length of pug embryos showed no
Fig. 1. pug animals display reduced skeletal element length. (A) graph showing pug skeletal element lengths compared to control littermates at various ages. Values are
normalized such that control element lengths are set to 100%. Embryonic pug skeletons display a 15–20% reduction in skeletal element length beginning at e14.5 compared
to their littermates. As adults, the severity of skeletal length reduction increases to 40% in proximal stylopod elements (ex. humerus), but remains at 20% in more distal
zeugopod (ex. ulna) elements. (B)–(E) e14.5 and e16.5 skeletons; red¼bone marked by alizarin red staining; blue¼cartilage marked by alcian blue staining. e14.5 pugmutant
limb elements are shorter than controls ((D) bracket). At e16.5, pug mutants show a similar crown-rump length and ribcage size compared to controls ((B) and (C)), but
shorter limb elements ((E) bracket), as well as a shorter mandible (yellow arrows in ((B) and (C)). The decrease in element length is not accompanied by changes in skeletal
patterning or joint morphology during embryonic stages. ((F)–(H)), adult pug animals (postnatal day (P)119) show an overall reduction in body size, in addition to shortened
snouts, limbs, and tails compared to control littermates. (I)–(M) Adult skeletons (P119) stained with alizarin red. Adult skeletons reveal shortening of the skull (yellow arrows
in (I) and (K) mark the mandible length) and limbs with more pronounced shortening of proximal limb elements ((L) and (M)) compared to littermate controls. Adult pug
animals also display a smaller ribcage and broadening of the ribs (arrowheads in (K) and insets). Scale bar in B¼0.25 cm, scale bars in D¼0.25 mm, scale bars in E¼0.5 mm,
scale bars in (I)–(M)¼0.5 cm.
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difference compared to controls (Fig. 1B and C), reduced skeletal
element length was observed in other bones (ex. mandible Fig. 1B and
C) that suggested a general defect in endochondral ossiﬁcation.
Skeletal defects in pug mutants become progressively worse with age
Bone development is not complete at birth. In the mouse, elonga-
tion and growth of the axial and appendicular skeleton continues
throughout postnatal development until twelve weeks after birth. To
test whether the pug phenotype merely represented a delay in
embryonic skeletal development, we generated and analyzed pug
homozygous adults. Homozygous pug mutants are semi-viable, com-
prising only 7.4% (n¼20/270) of animals weaned from crosses
between heterozygotes instead of the expected 25%. Though the cause
of pre-wean age mortality was not directly investigated, compression
of the lung cavity due to defects in the ribcage (see below) could cause
respiratory distress. Alternatively, the small size of pug homo-
zygotes could place them at a competitive disadvantage for nursing.
Homozygous pug animals that survived to adulthood are fertile,
appeared to have a normal life expectancy, and continued to show a
dwarfed appearance, including a shortened snout, shorter overall body
size, and short limbs (Fig. 1F–M). Interestingly, adult pug animals
showed increased severity of the skeletal phenotype compared to
embryos. At embryonic stages, no obvious differences were observed
in the morphology of the ribs (Fig. 1B and C), while pug adults
displayed a much smaller ribcage, with short, thick ribs (Fig. 1F and G,
arrowheads). In addition, pug adults showed rhizomelic or dispropor-
tionate shortening of the limbs. While zeugopod elements were 20%
shorter than controls, a similar reduction as observed in embryos,
stylopod elements were reduced by 40% (Fig. 1A and L–M).
In humans, rhizomelic shortening of the limbs is a key feature of
multiple skeletal dysplasias including achondroplasia, Ellis-van Creveld
syndrome, and thanatophoric dysplasia (Azouz et al., 1998; Baldridge
et al., 2010; Peraita-Ezcurra et al., 2012), suggesting that the pug
mutant is a new animal model to understand the molecular and
cellular mechanisms underlying these defects.
Fig. 2. Adult pug homozygotes display defects in trabecular architecture. (A)–(A)″ uCT scans of pug and control femurs revealed defects in trabecular bone content within the
diaphysis in pugmutants. Speciﬁcally, there is a greater density of trabecular bone at the distal head of the bone in pug and a reduction in trabecular bone along the length of
the bone ((A) lines mark the length of trabecular bone region). Within the region containing trabecular bone, in pug mutants, the organization appears altered compared to
controls (A′), with some regions showing higher density and others displaying lower density. In contrast, pug mutant cortical bone appears relatively normal (A″). (B) graph
showing several measurements of trabecular and cortical bone. Values are normalized such that control measurements are set to 1. pug femurs displayed an increase in
trabecular volume, thickness, space and connective density, but a reduction in trabecular number (B). No signiﬁcant changes were observed in cortical bone density or
structure in pug femurs while small, but signiﬁcant decreases were observed in endosteal and periosteal radii (B). (C) graph showing several additional measurements of
trabecular and cortical bone. Values are not normalized. While the degree of anisotrophy did not change in pug mutants, the polar moment of inertia was signiﬁcantly
decreased. We also observed changes in the structural model index that indicated a shift from rod-like trabecular bone towards plate-like bone in pug animals (C). Tb.BV/TV—
trabecular bone volume/total volume; Tb.N—trabecular number; Tb.Th—trabecular thickness; Tb.Sp—trabecular space; Conn.D—connective density; Ct.BV/TV—cortical bone
volume/trabecular volume; Ct.Th—cortical thickness; endo.radius—endosteal radius; peri.radius—periosteal radius; SMI—structural model index; DA—degree of anisotrophy;
pMOI(mm4)—polar moment of inertia. nnpo0.005, nnnpo0.0005.Scale bar in A¼1 mm, scale bars in (A)′ and (A)″¼100 μm.
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Adult pug bones display structural defects
The persistent shortening of adult pug limb elements demon-
strated that the embryonic phenotype is not due to a delay in
skeletal development. In addition, the adult phenotype suggested
that there might also be underlying structural defects in the bones.
To test this, micro Computer Tomography (μCT) was performed on
adult animals after the cessation of postnatal growth. μCT demon-
strated an increase in the ratio of trabecular bone volume over
total volume in pug adult femurs, while the full bone scans
revealed signiﬁcant changes in trabecular architecture in pug
adults (Fig. 2A and C). Trabecular bone volume, thickness, space,
and connective density were all increased in pug, while trabecular
number was reduced, indicating a tighter packing of trabecular
bone in the epiphysis (Fig. 2B). This increase in trabecular bone
volume in the epiphysis in pug adult femurs corresponds to a
reduction in trabecular bone within the diaphysis, resulting in a
signiﬁcant alteration in trabecular bone distribution within the
whole element (Fig. 2A′). Cortical bone forms by direct differentia-
tion of the perichondrium into bone forming cells. Strikingly,
no major changes in cortical bone structure were observed
(Fig. 2A″ and B), suggesting that the primary defect in pugmutants
is due to changes in endochondral ossiﬁcation. Though cortical
bone volume and density were unchanged, the periosteal
and endosteal radius of pug femurs was slightly decreased,
potentially leading to a weakening of long bones in pug adults.
No evidence of altered joint morphology or other morphological
defects were observed. In an attempt to deﬁne the primary defect
in pug mutants, we further examined embryonic skeletal develop-
ment.
Fig. 3. The maturing chondrocyte domains are reduced in pug skeletal elements. (A)–(B)″′ hematoxylin and eosin stained parafﬁn-embedded sections of the proximal
humerus heads at e16.5. Histological analysis revealed a reduction in the sizes of all states of maturing chondrocytes. Speciﬁcally, insets in (A)′ and (B)′ show an increased
density of resting chondrocytes in pug compared to controls (quantiﬁed in (C)). Column formation in proliferative chondrocytes in (A)″ and (B)″ show little difference
between pug and controls, though cells appear more tightly packed. Changes to both the height (D) of the hypertrophic chondrocyte domain and number of hypertrophic
chondrocytes along the axis of growth (E) can be seen in pug ((A)″′ and (B″′)). (F) Serial sections of OCT-embedded e16.5 distal humerus heads, at the junction with the
radius/ulna. The humeral heads are outlined by dotted lines. Within the skeletal elements, pug mutant chondrocytes maintain their molecular signature by appropriately
expressing Sox9 and Col2a in resting, columnar and prehypertrophic regions and ColX in hypertrophic regions (B). RC—resting chondrocytes, CC—columnar chondrocytes,
PC—prehypertrophic chondrocytes, HC—hypertrophic chondrocytes, B—bone. Scale bars in (A)–(B)¼100 μm, scale bars in (A)′—(B)″′¼50 μm, scale bars in F¼100 μm.
nnnpo0.000001, *po0.05.
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Fig. 4. Proliferation is unchanged and does not account for reduced bone length in pugmutants. (A) sections of humeral heads at e13.5 (outlined in white), showing phospho-histone
H3 (pHH3) staining in red, DAPI in blue. (B) graph showing themitotic indices of control and pug chondrocytes based on pHH3 staining. During early chondrocyte organization at e13.5,
proliferation is unchanged between pug and controls. Representative regions used for mitotic index quantiﬁcation are marked by yellow boxes in (A). (C) and (D), hematoxylin and
eosin-stained sections of humeri at e13.0 (C) and e13.5 (D). At e13.0 and e13.5, pug humeri display evidence of premature maturation in the center of the element, as shown by cell
morphology ((C) and (D), yellow bars). (E) and (F) serial sections of (C) and (D) marked by ColX in situ hybridization (blue) and counterstained with nuclear fast red (in pink). These
elements also display a premature (E) and broadened (F) domain of ColX expression in pug mutants, indicating maturation into hypertrophic chondrocytes. (G) dorsal view of e18.5
hindlimbs, anterior is to the right, showing early ossiﬁcation (red) of the talus and expanded ossiﬁcation of the calcaneus (red asterisks). (H) ventral view of cervical and thoracic
vertebrae showing premature ossiﬁcation in the cervical region and T1 at e16.5 (red arrowhead). In (G) and (H) red¼bone marked by alizarin red staining; blue¼cartilage marked by
alcian blue staining. C—calcaneus; T—talus; C7—seventh cervical vertebra; T1—ﬁrst thoracic vertebra. Scale bars in (A)–(F)¼50 μm, scale bars in G¼250 μm, scale bars in H¼500 μm.
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Chondrocyte identity is speciﬁed normally in pug mutants
To assess embryonic skeletal development in pug mutants, we
focused on the limbs and examined the morphology and mole-
cular proﬁles of the developing chondrocytes. Histological com-
parison of chondrocyte domains at e16.5 revealed that
chondrocytes in all stages of maturation were present, including
resting, columnar, prehypertrophic and hypertrophic, but the sizes
of their domains were reduced in pug compared to wild type
(Fig. 3A and B). Analysis of the resting chondrocyte domain
revealed a tighter packing of resting chondrocytes at the heads
of pug skeletal elements compared to controls (Fig. 3C) suggesting
a potential defect in chondrocyte size or in the ECM surrounding
the resting chondrocytes.
We further observed that the domain of columnar chondro-
cytes was reduced in pug, and that the cells appeared to be more
tightly packed. However, the overall organization of chondrocytes
within columns was comparable to controls, indicating that
chondrocytes are able to progress through early maturation stages
(Fig. 3A″ and B″). In later maturation stages, we observed a
decrease in the height of the prehypertrophic and hypertrophic
domains in pug mutants (Fig. 3A″′, B″′ and D) however this did not
appear to be due to tighter packing of chondrocytes but rather to
fewer cells along the axis of growth (Fig. 3E), indicating an
alteration in pug chondrocyte maturation.
We examined several markers of chondrocyte maturation to
test whether maturation was proceeding normally in pugmutants.
Sox9, a general chondrogenesis marker expressed in resting,
columnar and prehypertrophic chondrocytes (Zhao et al., 1997) is
expressed normally in pug chondrocytes (Fig. 3F). Col2a1a, the
cartilage speciﬁc form of Collagen 2, is also broadly expressed in
chondrocytes and is upregulated in prehypertrophic chondrocytes
(Cheah et al., 1991; Zhao et al., 1997) while ColX, is speciﬁcally
upregulated in hypertrophic chondrocytes (Gibson and Flint,
1985). We largely observed a similar pattern of expression of
these markers in pug and wild type animals suggesting that
although domains of maturing chondrocytes are smaller in pug,
they maintain normal identity and express the appropriate mar-
kers for their maturation status (Fig. 3F). The upregulation of
Col2a1a in prehypertrophic chondrocytes was not as obvious in
pug mutants compared to controls suggesting that the transition
from columnar to prehypertrophic chondrocytes may not be
completely normal in pug mutants, however prehypertrophic
chondrocytes appear morphologically normal. Together, these data
show that all types of chondrocyte are present and express the
typical complement of markers in pug embryos.
Chondrocyte proliferation is unchanged in pug mutants
The reduced sizes of the pug skeletal elements and chondrocyte
domains suggested that the primary defect could lie in chondro-
cyte proliferation or maturation. Decreased cell division in either
the resting or columnar chondrocyte pools could reduce the
terminal size of a skeletal element. To test this, we calculated a
mitotic index using phosphorylated histone H3 staining. If pro-
liferation defects cause the pug phenotype, we would expect to see
a reduction in the mitotic index; however, we observed no
signiﬁcant change in proliferation rate in pug (1.74% (70.4))
compared to wild type (1.66% (70.5)) at e13.5 (Fig. 4A and B).
To test whether altered proliferation contributed to the more
pronounced pug phenotype at later stages, we analyzed BrdU
incorporation and pHH3 staining at e16.5 and e18.5 but did not
observe any signiﬁcant difference compared to controls (data not
shown). Given that pug skeletal elements are already signiﬁcantly
reduced by e14.5, changes in proliferation do not appear to cause
the initial reduced size of pug skeletal elements nor do they
exacerbate the phenotype during later embryonic development.
Chondrocytes mature more rapidly in pug mutants
To determine if changes in maturation could cause dwarﬁsm in
pug homozygotes, we analyzed chondrocytes at multiple stages of
bone development. In early e13 embryos, just after the cartilage
template has formed, wild-type skeletal elements primarily con-
tained resting chondrocytes. In contrast, pug skeletal elements
already contained distinct prehypertrophic and hypertrophic-like
chondrocytes at the center of the element, which had initiated
ColX expression, a hypertrophic chondrocyte marker (Fig. 4C and
E). By e13.5, pug skeletal elements contained a broader domain of
hypertrophic-like chondrocytes, based on morphology and ColX
expression, compared to wild-type elements (Fig. 4D and F). The
overall size of the skeletal elements was comparable between pug
and wild type at e13.5 (see Fig. 5A and D), demonstrating that
premature chondrocyte maturation preceded changes in element
length. This suggests that premature initiation of chondrocyte
maturation is the primary defect in pug mutants, leading to
smaller skeletal elements. We observed other examples of pre-
mature maturation at later stages in pug embryos including
premature ossiﬁcation of the talus in the hindlimb at e18.5
(Fig. 4G) and cervical vertebrae at e16.5, (Fig. 4H). These data
suggest that the gene affected in pug mutants normally curbs
chondrocyte maturation in skeletal elements that form through
endochondral ossiﬁcation.
The pug mutation results in increased Ihh signaling
Several signaling pathways including Ihh tightly regulate the
timing and rate of chondrocyte maturation. Ihh is expressed in
prehypertrophic chondrocytes, and activates short-range down-
stream targets such as Gli1, Ptch1, and Runx2 to regulate matura-
tion and promote proliferation (Gritli-Linde et al., 2001; Karp et al.,
2000; Mak et al., 2008; St-Jacques et al., 1999; Enomoto et al.,
2000; Enomoto-Iwamoto et al., 2001; Takarada et al., 2013; Takeda
et al., 2001). To test if alterations in Ihh signaling could underlie
the maturation defect in pug mutants, we examined the expres-
sion of these genes at early stages of skeletal element formation. In
young e13 embryos we did not observe major changes in the direct
targets of Ihh signaling (Ptch1 and Gli1) within chondrocytes,
despite a broadened domain of Ihh expression in pug mutants
(Fig. 5A and C′). Additionally, no changes were observed in Runx2
expression in pug where is it expressed throughout the center of
the element and in the surrounding mesenchymal cells (Fig. 5D
and D′). This suggests that the premature maturation of pug
chondrocytes occurs independently of changes in Ihh signaling.
By e13.5, we observed increased Ptch1 expression in pug chon-
drocytes and perichondrial cells compared to controls (Fig. 5F and
F′), as well as increased Gli1 expression within pug chondrocytes,
ﬂanking the Ihh domain (Fig. 5G and G′). Runx2 is also expressed
in a broader domain at e13.5 in pug mutants, which likely reﬂects
the expanded domain of maturing chondrocytes marked by Ihh
expression (Fig. 5E, E′ and H–H′). The observed increase in the
levels of short-range Ihh targets persists at later stages, including
e16.5 (Fig. 5L and N′). The apparent increase in short-range Ihh
signaling early is likely a secondary effect of premature matura-
tion, which causes a broader domain of cells to express Ihh.
The pug mutation does not inhibit PTHrP
Ihh also signals long range to PTHrP, which protects the
proliferating pool of chondrocytes at the heads of bones by
inhibiting chondrocyte maturation (Karaplis et al., 1994; Lanske
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Fig. 5. Short-range Ihh signaling increases after the onset of premature maturation in pug skeletal elements. (A)–(H)′, (J)–(J)′, (L)–(N)′, sections through humeri at the stages indicated
showing in situ hybridizations for probes as indicated (in purple), and counterstained with nuclear fast red (in pink). At e13, when premature chondrocyte maturation has begun in pug,
Ihh expression is expanded ((A) and (A′)), but the expression of the direct targets Ptch1 and Gli1 are similar between size-matched wild type and pug animals ((B)–(C′)), as is the
expression of Runx2 ((D)–(D′)). Within 12 h, the broad domain of Ihh in pug animals ((E)–(E′)) is matched by increased short-range Ihh signaling as reﬂected by expanded Ptch1 and Gli1
expression ((F)–(G′)), and a broader domain of Runx2 expression ((H)–(H′)). (I) and (I)′, (K)–(K)′, wholemount e13.5 ((I)–(I′)) and e14.5 ((K)–(K′)) limbs of pug mutants and controls
carrying one copy of PTHrP-LacZ, stained for βgalactosidase activity (in blue). No obvious changes were observed in long-range signaling, indicated by similar patterns of PTHrP-LacZ
((I)–(I′)), (K)–(K′)). Closer analysis of PTHrP-LacZ by in situ hybridization shows no reduction in PTHrP expression in pug ((J)–(J′)). Increased Ihh signaling is maintained throughout
embryonic development ((M)–(N′), marked by Ptch1 and Gli1) even though the domain of Ihh expressing cells decreases ((L)–(L′)). Scale bars in (A)–(H′), (J)–(J′), (L)–(N′)¼100 μm, scale
bars in (I)–(I′)¼500 μm, scale bars in (K)–(K′)¼250 μm.
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et al., 1996; Vortkamp et al., 1996). Reduction or loss of PTHrP
expression in resting chondrocytes can lead to dwarﬁsm.
To determine if this caused the pug phenotype, we used a
PTHrP-lacZ reporter mouse line to follow PTHrP expression (Chen
et al., 2006). However, we did not observe any noticeable changes
in PTHrP-lacZ expression at early (e13.5) or late (e14.5–e18.5)
embryonic stages (Fig. 5I and K′ and not shown) in pug mutants.
While some variability was evident in the staining, we did not
observe a decrease in PTHrP expression either by whole mount
analysis or section in situs (Fig. 5J–J′). These data suggest that
long-range Ihh signaling is not reduced by the pug mutation and
that premature maturation is not due to loss of PTHrP expression.
The pug mutation does not affect Fgf signaling through ERK1/2 in
chondrocytes
Fgf signaling also plays a key role in regulating chondrocyte
maturation, and activating mutations in Fgfr3 cause achondroplasia,
(Amizuka et al., 2004; Deng et al., 1996; Rousseau et al., 1994)
suggesting that changes in Fgf signaling might contribute to the pug
phenotype. Instead, we observed similar expression of Fgfr3 in young
e13 pug mutants and controls (Fig. 6A and B). Subsequently, Fgfr3
expression became increased in the center of pug skeletal elements by
e13.5 compared to controls (Fig. 6C and D), similar to the increase in
short-range Ihh signaling at this timepoint. This increased expression
of Fgfr3 was maintained throughout embryonic development (Fig. 6E
and F). However, the increased Fgfr3 levels in pug mutants do not
cause increased Fgf signaling through ERK1/2. We observed similar
levels of phosphorylated ERK1/2 (pERKþ) nuclei in pug mutants and
controls at e13.5 (Fig. 6G and H). In control e13.0 resting chondro-
cytes, 1.91% (70.19%) of nuclei were pERKþ compared to 1.93%
(70.025%) in pug resting chondrocytes, while control columnar
chondrocytes displayed 1.99% (70.56%) pERKþ nuclei compared to
1.90% (70.26%) in pug columnar chondrocytes. These data suggest
that the changes in Fgfr3 expression may reﬂect changes in chon-
drocyte maturation but do not cause the premature initiation of
maturation in pug embryos. Together, these data show that premature
chondrocyte maturation in pugmutants is not due to changes in early
Ihh or Fgf signaling, two key pathways that regulate maturation.
Fig. 6. Fgfr3 expression increases after the onset of premature maturation but does not lead to increased signaling through ERK1/2. (A)–(F) sections through humeri at the
stages indicated showing in situ hybridizations for Fgfr3 (in purple), and counterstained with nuclear fast red (in pink). At e13, the expression of Fgfr3 appeared similar
between control and pug animals ((A)–(B)), and levels increased at the center of pug elements by e13.5 ((C)–(D)). As embryonic development proceeds, this increase in Fgfr3
expression is maintained ((E)–(F)). (G) and (H) sections through e13.5 humeri stained for phosphorylated Erk1/2 (in brown). Increased Fgfr3 expression at e13.5 does not
result in an increase in Fgf signaling, as evidenced by similar pERK positive cells in controls and pug animals in both the resting and columnar chondrocyte pools ((G) and
(H)), red arrowheads). Scale bars in (A)–(F)¼100 um, scale bars in (G) and (H)¼20 μm.
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The pug mutation affects the Xylosyltransferase 1 (Xylt1) gene
To determine the molecular lesion responsible for the pug
phenotype, the locus was narrowed to a 7.83 MB interval on
Chromosome 7 using meiotic recombination mapping. We then
used Sequence Capture and Illumina sequencing to identify the
causative mutation (see Materials and methods section for details).
This approach identiﬁed an exonic T to A transversion (c.T2794A)
near the 3′ end of the Xylosyltransferase 1 (Xylt1) gene. We
conﬁrmed that this mutation segregated with the pug phenotype
using Sanger sequencing (Fig. 7A). The pug mutation results in a
missense mutation in the Xylt1 protein (W932R) affecting a
residue that is highly conserved from humans to Caenorhabditis
elegans (Fig. 7B and C). The initial step in the addition of GAG
chains to all proteoglycans requires the transfer of xylose to
speciﬁc serine residues on the core protein (Muller et al., 2006;
Roch et al., 2010; Schön et al., 2006a; Stoolmiller et al., 1972). In
vertebrates, this process is catalyzed by two xylosyltransferases,
Xylt1 and Xylt2. These proteins share considerable identity in the
xylosyltransferase domain (470%) and appear to have similar
enzymatic activity (Condac et al., 2007; Cuellar et al., 2007;
Ponighaus et al., 2007; Roch et al., 2010).
Xylt1 is speciﬁcally expressed in chondrocytes of developing skeletal
elements
To better understand when and where Xylt1 may be acting
during mouse skeletal development, we ﬁrst examined the
expression pattern of the Xylt1 transcript in mouse embryos. In
the developing skeleton, Xylt1 mRNA is strongly expressed in all
chondrocytes, beginning before e13.5 (Fig. 7D and data not
shown). As chondrocytes within the skeletal element mature, they
maintain Xylt1 expression until they have hypertrophied but Xylt1
transcripts were not observed in mature bone (Fig. 7D and data
not shown). Xylt1 transcripts were also not observed in non-
skeletal tissue types, suggesting that during mid to late embryonic
development, Xylt1 may function exclusively in the axial and
appendicular skeleton. Xylt1 and Xylt2 are expressed in a highly
overlapping pattern in the adult mouse (Condac et al., 2007).
Fig. 7. The pug mutation affects the Xylosyltransferase 1 gene, which is speciﬁcally expressed in chondrocytes. (A) sequencing traces from wild-type, heterozygous and
homozygous pug mutant samples showing a T-A transversion mutation in pug mutants and carriers. The pug mutation causes a missense (W932R) in the Xylt1 protein.
(B) schematic of the mouse Xylt1 protein highlighting the transmembrane domain, core 2/I-branching and Xylosyltransferase domains. The pug mutation occurs in near the
C-terminus of Xylt1 (red line), outside of any known protein domains. (C) Alignment of the C-terminus of Xylt1 orthologs across multiple animal lineages. The mutated
tryptophan residue (W932 in mouse) is highly conserved. (D) sections through wild-type forelimb skeletal elements at several stages, showing in situ hybridization patterns
for Xylt1 transcripts (purple) and counterstained with nuclear fast red (in pink). Xylt1 transcripts are speciﬁcally found in developing skeletal chondrocytes, with strong
expression from e13.5 through birth. (E)–(H), sections through e16.5 humeri, showing close-ups of resting chondrocytes. Xylt1 normally localizes to the cis-Golgi ((E) and
(F)), however this localization is lost in the pug mutant ((G) and (H)). DAPI marks nuclei (blue) and GM130 marks the cis-Golgi (red). In cell types that did not show any
evidence of Xylt1 transcripts by in situ hybridization, the Xylt1 antibody appeared to localize to discrete punctae within the cell similar to the pattern observed in pug
mutants (H). Scale bars in (D) (e13.5 and e16.5)¼250 μm and (e18.5)¼100 μm, scale bars in (E)–(H)¼10 μm.
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However, we found no evidence of Xylt2 expression during
embryonic development in control embryos (not shown), consis-
tent with gene expression database reports for Xylt2 (Diez-Roux
et al., 2011; Visel et al., 2004). We did not observe Xylt2 expression
in pug mutants at embryonic stages indicating that Xylt2 is not
upregulated to compensate for the loss of Xylt1 function in pug
mutant chondrocytes.
The pug mutation disrupts Xylt1 protein localization
The pug mutation affects a residue 21 amino acids from the
C-terminus of Xylt1 (Fig. 7C). Polyphen and SIFT analyses
(Adzhubei et al., 2010; Kumar et al., 2009) suggest that the
substitution of an Arginine for a Tryptophan at this position is
likely deleterious to the protein; however, this site is not within
Fig. 8. The pug mutation strongly reduces xylosyltransferase activity in chondrocytes, curtailing proteoglycan processing. (A) and (B) graphs showing xylosyltransferase
activity in cell lysates from isolated chondrocytes (A) or transfected CHO cells (B). Values are normalized such that control activity is set to 100%. In xylosyltransferase assays
using whole cartilage from P0 embryos, pug cartilage showed an 80% reduction in activity compared to control cartilage using both bikunin and chick aggrecan as acceptor
proteins (A). In cell culture, the pug allele of Xylt1 also showed 80% reduction in activity compared to a wild type Xylt1 construct when overexpressed in chinese hamster
ovary (CHO) cells or in CHO cells deﬁcient in xylosyltransferase activity (CHO 745) (B). (C) and (C′), graphs showing percentage of radio-labeled, newly-synthesized GAG
chains per mg of limb cartilage protein, after 24 h incubation in [35S] sulfate-containing media. (C′) is an expanded view of chondroitinase-treated samples shown in (C). The
overall incorporation of sulfate onto newly-synthesized GAG chains is reduced by 40% in pug cartilage compared to controls. Fractionating the total sulfate incorporated
counts in CsCl density gradients shows a 50% reduction in the modiﬁcations on high-density proteoglycans, and a subsequent increase in low-density proteoglycans likely
due to incompletely processed large molecular weight proteoglycans (C). Digestion with chondroitinase (ChABC) removes CS-GAG chains from the analysis and revealed a
reduction in the sulfation of non-CS-GAGs in pug samples (C′). (D) sections of humeri at stages indicated, stained for Safranin O (orange-brown), which marks GAG chains.
Reduced GAG chains in pug cartilage compared to controls could be observed in vivo by diminished Safranin O staining at several developmental stages (D) Staining outside
of skeletal elements at 13.5 reﬂect the early extracellular matrix comprised of versican and other proteglycans. Scale bars in D¼100 μm.
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any of the known functional domains in Xylt1. In order to
determine how the W932R missense mutation affects Xylt1
protein, we ﬁrst examined the subcellular localization of the
protein within chondrocytes. In previous studies, Xylt1 has been
shown to act in the Golgi where it catalyzes the xylosylation of
proteoglycan core proteins, (Cardin and Weintraub, 1989; Muller
et al., 2006; Schön et al., 2006a; Stoolmiller et al., 1972). Consistent
with this, we observed colocalization of Xylt1 protein with the cis-
Golgi marker GM130 in wild-type chondrocytes (Fig. 7E and F).
Strikingly, in pug chondrocytes Xylt1 was not observed in the cis-
Golgi (Fig. 7G and H) suggesting that the missense mutation
affects localization of the Xylt1 protein and thus alters its normal
function within the Golgi.
The pug mutation causes reduced xylosyltransferase activity
The reduced levels of Xylt1 in the cis-Golgi in pug mutants
could be the primary defect as xylosyltransferases are thought to
function primarily in this organelle. However, to test whether the
W932R mutation also affected activity of the Xylt1 protein, we
measured the ability of Xylt1 to transfer xylose onto proteoglycan
core proteins both in vivo and in cell culture. Using proximal
hindlimb cartilage from postnatal day 0 (P0) neonates, we
observed only 20% xylosyltransferase activity in pug mutants
compared to controls (Fig. 8A). This dramatic reduction in xylosyl-
transferase activity was found using proteins with either single
(bikunin) or multiple (aggrecan core protein) acceptor sites. As
mentioned previously, we did not detect Xylt2 transcripts in
control or pug mutant animals. To determine if the remaining
xylosyltransferase activity in pug cartilage could be due to func-
tional Xylt2 that was below our level of detection, we examined
Xylt1 activity in cultured cells. Speciﬁcally, we expressed wild-type
and pug alleles of Xylt1 in both wild type and xylosyltransferase
deﬁcient CHO-745 cells (Esko et al., 1985). Consistent with our
observations in cartilage, Xylt1 protein carrying the pug mutation
exhibited reduced activity comparable to 10-20% of the wild-
type Xylt1 activity (Fig. 8B). These data indicate that pug animals
carry a hypomorphic mutation and that Xylt1W932R retains a
low level of xylosyltransferase activity. The similar reduction in
Xylt1W932R activity in vivo and in cell culture suggests that Xylt2
does not compensate for reduced Xylt1 activity in pug mutant
chondrocytes.
The pug mutation reduces xylosyltransferase-dependent GAG chain
modiﬁcations on proteoglycans
Two major classes of proteoglycans, heparan sulfate proteogly-
cans (HSPGs) and chondroitin sulfate proteoglycans (CSPGs), are
highly expressed in chondrocyte extracellular matrix and have
been shown to play a key role in regulating chondrocyte matura-
tion (Cortes et al., 2009; Koziel et al., 2004). Xylosyltransferases are
essential for normal proteoglycan processing and function (Baeg
et al., 2001; Cortes et al., 2009; Nybakken and Perrimon, 2002;
Venkatesan et al., 2012; Yan and Lin, 2009), thus the pug mutation
should negatively affect normal proteoglycan processing within
chondrocytes. To test this, we analyzed sulfate incorporation in
isolated P0 cartilage as a measure of proteoglycan processing
(Domowicz et al., 2000). pug cartilage showed a 34% reduction
in total proteoglycan sulfation compared to control cartilage
(Fig. 8C). We then separated the proteoglycan samples into low-
density and high-density fractions on dissociative CsCl gradients.
We observed that the strongest decrease in sulfate incorporation
occurred in the high-density proteoglycan fraction in pug mutants,
which in cartilage is composed primarily of aggrecan, a CSPG
normally modiﬁed by hundreds of GAG chains. Digestion with
chondroitinase revealed that the proteoglycans that are partially
processed in pug are primarily members of the CSPG class (Fig. 8C′).
However, the undigested portion of proteoglycans, including
HSPGs, also displayed reduced sulfation in pug, suggesting that
the pug mutation affects the ability of Xylt1 to add GAG chains to
multiple classes of proteoglycans. To test whether the reduced
xylosyltransferase activity observed in our assays causes GAG chain
defects in vivo, we stained wild type and pug skeletal elements
with Safranin O, a marker of sulfated GAG chains (Rosenberg, 1971).
We observed a strong reduction in Safranin O staining in pug
mutant skeletal elements compared to wild type at both early and
late stages in skeletal development (Fig. 8D), indicating that the
decrease in Xylt1 activity translates into a reduction in proteoglycan
processing in cell culture and in vivo.
Discussion
The vertebrate skeleton is laid down and undergoes signiﬁcant
patterning and differentiation during embryogenesis. Defects in
skeletal development can affect the size and morphology of the
bones, but also the structure and strength of these elements
throughout the life of the organism. Though the major signaling
pathways that regulate endochondral ossiﬁcation have been well
characterized, the interplay between these signaling factors and
the extracellular matrix within the developing skeleton is just
beginning to be appreciated. Xylt1, as a major regulator of
proteoglycan processing in chondrocyte maturation, maintains
the integrity of the extracellular matrix. Defects in xylosyltransfer-
ase function in the cartilage affect not only the formation of a
proper proteoglycan network, but also affect signaling within the
developing growth plate to prematurely initiate chondrocyte
maturation and subsequently alter the structure of adult bone.
Xylt1 is essential for normal maturation of skeletal chondrocytes
Proteoglycans, particularly HSPGs and CSPGs, play critical roles
in endochondral skeletal development. The proper function of
proteoglycans depends upon the polysaccharide moieties, the
glycosaminoglycan side chains that are added to the core protein.
Mutations in HSPG or CSPG core proteins or in the enzymes that
modify their GAG chains affect chondrocyte maturation, prolifera-
tion and ossiﬁcation (Cortes et al., 2009; Domowicz et al., 2009;
Hilton et al., 2005; Ratzka et al., 2008; Watanabe et al., 1994, 2010;
Wilson et al., 2012). Xylosyltransferases play the crucial ﬁrst step
in the initiation of GAG chain synthesis on HSPGs and CSPGs by
adding a xylose to speciﬁc serine residues on the core proteins
(Cuellar et al., 2007; Esko et al., 1985; Muller et al., 2006;
Ponighaus et al., 2007; Prante et al., 2006). Following xylosylation,
additional sugar moieties are added resulting in a tetrasaccharide
linker, followed by varying lengths of disaccharide units (condroi-
tin, heparan, dermatan or keratan sulfate) (Schwartz, 2000). We
show that a hypomorphic Xylt1 mutation in pug animals strongly
reduces xylosyltransferase activity in the developing skeleton, and
leads to reduced GAG chains in skeletal elements and premature
chondrocyte maturation. This has a profound effect on the endo-
chondral skeleton and leads to disproportionate dwarﬁsm in pug
homozygous mice.
Decreased xylosyltransferase activity in pug mutants leads to
signaling defects
Previous studies in both vertebrates and invertebrates have
uncovered important roles for GAG chains in regulating morpho-
gen gradient formation through the direct binding of signaling
molecules (Cortes et al., 2009; Yan and Lin, 2009). HSPGs have
been implicated as major regulators of Fgf diffusion within the
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ECM, both in ﬂies and in mammalian systems, and more recently
in regulating Ihh diffusion within the ECM (Baeg et al., 2001;
Cardin and Weintraub, 1989; Kalinina et al., 2009; Koziel et al.,
2004; Nybakken and Perrimon, 2002). In addition, recent work
indicates that proper CSPG processing plays an important role in
allowing Ihh to diffuse through the extracellular matrix surround-
ing chondrocytes (Cortes et al., 2009). Ihh and Fgfs normally act to
prevent chondrocyte maturation, and as the pug mutation affects
both HSPGs and CSPGs, one prediction would be that both of these
signaling pathways should be affected in pug mutants, and thus
would affect maturation rate. Indeed, we observed an upregula-
tion of short-range Ihh signaling as well as an increase in Fgfr3
levels. In the case of Fgfr3, no downstream changes in MAPK
signaling were observed, and long-range Ihh signaling through
PTHrP, which normally inhibits chondrocyte maturation, was not
affected in pug mutants. This indicates that changes in Ihh and Fgf
signaling likely do not drive the premature maturation of pug
chondrocytes. Interestingly, CSPGs and HSPGs appear to have
opposing functions in regulating the diffusion of Ihh through the
ECM, with CSPGs acting to expand the domain of Ihh diffusion, and
HSPGs acting to restrict the domain of Ihh diffusion. As our pug
mutant appears to affect both CSPGs and HSPGs, we observed an
alteration in the level of signaling propagated within Ihh-receiving
cells, indicating an increase in the efﬁcacy of the Ihh signal in a
processed proteoglycan-deﬁcient growth plate.
Strikingly, we found that the maturation of chondrocytes
occurs approximately half a day earlier in pug mutants than in
wild type and prior to changes in Fgf and Ihh signaling pathways.
However, after premature maturation is initiated, Ihh target genes
become upregulated in the pug growth plate and surrounding
perichondrium. This short-range Ihh signaling drives maturation
and ossiﬁcation of perichondrial bone (Hammond, Schulte-Merker,
2009; St-Jacques et al., 1999) and the increase that we observed in
pug mutants may make the dwarﬁsm phenotype more severe by
driving premature ossiﬁcation of the perichondrium.
Though the pugmutation does not lead to complete loss of GAG
chain formation in the growth plate, the reduction in proteoglycan
processing is sufﬁcient to disrupt chondrocyte maturation. These
data reveal that proteoglycans not only regulate the diffusion of
key signaling molecules but also provide maturation cues to
chondrocytes, independent of Ihh and Fgf signaling. While the
mechanisms that underlie the decision to initiate maturation are
still unclear, the premature maturation phenotype observed in pug
in the absence of changes in signaling points to an extracellular
matrix-associated cue that deﬁnes and determines the normal
timing of chondrocyte maturation.
Xylt1 function is conserved across vertebrates
A recent study described the characterization of two zebraﬁsh
mutant lines carrying point mutations in the ortholog of Xylt1
(Eames et al., 2011). Similar to our ﬁndings, the zebraﬁsh Xylt1
gene is expressed largely in developing chondrocytes, and the ﬁsh
Xylt1 mutants displayed strong similarities to pug mutants includ-
ing premature maturation and ossiﬁcation of endochondral ske-
letal elements. Together, these data indicate that the role of Xylt1
during skeletal development is largely conserved across vertebrate
lineages.
Interestingly, there are distinct differences between the zebra-
ﬁsh and mouse Xylt1 mutants. Fish homozygous for Xylt1 muta-
tions do not show the dwarﬁsm we observe in pug mutants,
although they do show a shortened craniofacial phenotype, which
is also present in pug mutants. In addition, in contrast to pug
mutants that show reduced postnatal survival, homozygous Xylt1
zebraﬁsh mutants are completely viable. Finally, the ﬁsh study
noted a decrease in CSPG disaccharides but not HSPGs in their
Xylt1 mutants, while our sulfate incorporation assay suggests that
both CSPGs and HSPGs are affected by reduced Xylt1 function. One
explanation for the differences between the zebraﬁsh and mouse
Xylt1 mutant phenotypes is that they are due to the speciﬁc nature
of each mutation, which could be hypomorphic to different
degrees. Future studies on the xylosyltransferase activity of the
mutant zebraﬁsh Xylt1 alleles would help determine whether
these phenotypic differences are due to varying levels of activity
of the mutant isoforms or represent real differences in the
requirement for Xylt1 in mouse vs. ﬁsh development.
Xylosyltransferases and human health
Polymorphisms in XYLT1 and XYLT2 have been associated with
modifying the severity of pseudoxanthoma elasticum, a multi-
system disorder in humans involving mineralization of elastic
ﬁbers (Schön et al., 2006c). Xylosyltransferase activity has also
been used as a biomarker for several other diseases including
diabetic nephropathy, male infertility and osteoarthritis (Gotting
et al., 2002, 2007, 1999; Schön et al., 2006b). Most recently,
Schreml et al. (2013) identiﬁed a homozygous point mutation in
XYLT1 (c.C1441T) in two siblings exhibiting short stature and other
skeletal anomalies and developmental defects. Our studies show
that the pug mutant shares many of the phenotypes described in
the human patients carrying homozygous mutations in XYLT1,
including skeletal dysplasias, short stature, broadening of the ribs,
craniofacial defects, and progressive bone growth defects. Inter-
estingly, the human phenotypes appear milder than those
observed in pug homozygotes. These differences could be due to
the fact that XYLT1 protein levels are not reduced in patient cells,
nor was xylosyltransferase activity reduced in contrast to our
ﬁndings in pug mutants. The pug mutant mouse shows a more
severe skeletal growth defect than short stature and shares
deﬁning characteristics with human dwarﬁsm including rhizome-
lic shortening of long bones and thoracic kyphosis (Azouz et al.,
1998). This suggests that XYLT1 is a potential candidate for
additional cases of human dwarﬁsm or short stature syndrome
where the underlying genetic defect has yet to be determined.
Further characterization of the pug mutant has the potential to
reveal targets for effective treatment as well as the future
diagnosis of human dwarﬁsm cases resulting from primary defects
to the skeleton.
Xylt1 and Xylt2 display speciﬁcity in expression and functional
requirements
Xylt1 and Xylt2 are expressed in a highly overlapping pattern in
adult mice (Condac et al., 2007); however, the phenotypes of the
loss of function mutants reveal an elegant speciﬁcity for xylosyl-
transferases during development and in adults. The Xylt2 knockout
mouse displays no developmental defects, but develops liver cysts
postnatally (Condac et al., 2007). The liver is one of the few tissues
in the adult mouse that speciﬁcally expresses Xylt2, but not Xylt1.
In contrast, Xylt1 is primarily expressed in developing skeletal
elements and the defect in pug mutants is restricted to chondro-
cytes. The restriction of the pug phenotype to cartilage elements
and the Xylt2 phenotype to the liver suggests a redundancy in
xylosyltransferase function in other tissue types, both during
development and adult growth. However, the restricted expres-
sion pattern of Xylt1 during development, coupled with the lack of
Xylt2 expression during these stages argue against redundancy but
instead suggests that other proteins might act as xylosyltrans-
ferases to initiate GAG chain synthesis during embryonic devel-
opment. Analysis of pug-Xylt2 double mutants could reveal
redundancies in xylosyltransferase function during development
if Xylt1 and Xylt2 are expressed broadly, but at levels we could not
E.K. Mis et al. / Developmental Biology 385 (2014) 67–8280
detect in our analyses. Alternatively, the double mutants could
indicate a requirement for previously unidentiﬁed xylosyltrans-
ferases in the development of embryonic tissues.
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